Business Description
Cullinan Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US2300311063
Share Class Description:
CGEM: Ordinary SharesDescription
Cullinan Oncology Inc is a clinical-stage biopharmaceutical company that focuses on developing targeted oncology therapies without bias towards specific treatment modalities. Their mission centers on setting new standards of care for cancer patients by identifying high-impact cancer targets, defined as key oncogenic drivers or immune system activators. The company's strategy involves selecting optimal therapeutic modalities for these targets. Operating as a single reporting and operating segment, the company's core business is developing early-stage cancer therapeutics, aiming to address critical needs in oncology treatment. The company's pipeline consists of CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, CLN-617.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 130.1 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -46.5 | |||||
| 3-Year EPS without NRI Growth Rate | -39 | |||||
| 3-Year FCF Growth Rate | -65.1 | |||||
| 3-Year Book Growth Rate | 30.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74 | |||||
| 9-Day RSI | 64.83 | |||||
| 14-Day RSI | 60.17 | |||||
| 6-1 Month Momentum % | 69.47 | |||||
| 12-1 Month Momentum % | 49.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.07 | |||||
| Quick Ratio | 17.07 | |||||
| Cash Ratio | 16.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | -0.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -31.35 | |||||
| ROA % | -29.72 | |||||
| ROIC % | -298.48 | |||||
| ROC (Joel Greenblatt) % | -4228.38 | |||||
| ROCE % | -38.8 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.52 | |||||
| Price-to-Tangible-Book | 1.52 | |||||
| EV-to-EBIT | -1.68 | |||||
| EV-to-EBITDA | -1.69 | |||||
| EV-to-Forward-Revenue | 1.06 | |||||
| EV-to-FCF | -2.27 | |||||
| Price-to-Net-Current-Asset-Value | 1.53 | |||||
| Price-to-Net-Cash | 1.58 | |||||
| Earnings Yield (Greenblatt) % | -59.52 | |||||
| FCF Yield % | -19.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGEM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cullinan Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.69 | ||
| Beta | 0.3 | ||
| Volatility % | 62.02 | ||
| 14-Day RSI | 60.17 | ||
| 14-Day ATR ($) | 1.245487 | ||
| 20-Day SMA ($) | 17.1275 | ||
| 12-1 Month Momentum % | 49.17 | ||
| 52-Week Range ($) | 7.64 - 20.62 | ||
| Shares Outstanding (Mil) | 43.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cullinan Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cullinan Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cullinan Therapeutics Inc Frequently Asked Questions
What is Cullinan Therapeutics Inc(CGEM)'s stock price today?
The current price of CGEM is $16.07. The 52 week high of CGEM is $20.62 and 52 week low is $7.64.
When is next earnings date of Cullinan Therapeutics Inc(CGEM)?
The next earnings date of Cullinan Therapeutics Inc(CGEM) is 2024-05-10 Est..
Does Cullinan Therapeutics Inc(CGEM) pay dividends? If so, how much?
Cullinan Therapeutics Inc(CGEM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers